|1.||Berkenblit, Anna: 12 articles (01/2014 - 01/2009)|
|2.||Kurzrock, Razelle: 11 articles (07/2015 - 04/2011)|
|3.||Hidalgo, Manuel: 11 articles (08/2012 - 11/2002)|
|4.||Erlichman, Charles: 9 articles (05/2015 - 10/2006)|
|5.||Dancey, Janet E: 9 articles (12/2012 - 10/2002)|
|6.||Boni, Joseph P: 9 articles (06/2012 - 03/2004)|
|7.||Escudier, Bernard: 8 articles (10/2015 - 09/2008)|
|8.||Naing, Aung: 8 articles (07/2015 - 09/2011)|
|9.||Dancey, Janet: 8 articles (04/2014 - 11/2004)|
|10.||Motzer, Robert J: 8 articles (03/2014 - 12/2006)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2011 - "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer. "
01/01/2011 - "We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. "
05/11/2010 - "Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. "
10/01/2008 - "Temsirolimus demonstrates a significant improvement in overall survival in patients with advanced renal cell carcinoma and poor-prognostic features, thereby validating the importance of mTOR in the natural history of this disease. "
06/01/2012 - "Temsirolimus is an effective treatment for renal cell carcinoma. "
01/01/2011 - "Especially patients with a good response to previous antiangiogenic treatment, a good overall condition and a low Memorial Sloan Kettering Cancer Center (MSKCC) score benefited from subsequent treatment with temsirolimus. "
05/15/2014 - "However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are minimal. "
12/01/2015 - "Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors."
01/01/2015 - "Our results indicate some efficacy of temsirolimus in untreated patients with renal tumors and poor-intermediate prognosis, although the limitations of small sample size and retrospective nature must be taken into account. "
04/01/2015 - "A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report."
|3.||Kidney Neoplasms (Kidney Cancer)
02/01/2009 - "A prominent member in its class of medications, temsirolimus has already been shown to improve overall survival in advanced kidney cancer, when compared with the previous standard, IFN-alpha. "
01/01/2015 - "The aim of this study was to investigate the outcomes of an unselected group of patients with renal cancer treated with temsirolimus in a compassionate use program. "
08/01/2014 - "Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer."
06/01/2014 - "The procedure is applied to analyze the aforementioned renal cancer study and identify gene transcripts and possible time-interactions that are relevant to CCI-779 metabolism in peripheral blood."
06/15/2004 - "Based on our results, weekly doses of 25, 75, and 250 mg CCI-779 not based on classical definitions of maximum-tolerated dose are being tested in phase II trials in patients with breast and renal cancer."
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/01/2010 - "These findings suggest that mTOR signaling is a potential target of oral squamous cell carcinoma associated with bone destruction, and hence we describe the efficacy of temsirolimus for the treatment of advanced oral squamous carcinoma."
11/01/2010 - "In this study, we investigated the antitumor effect of temsirolimus-mediated mTOR inhibition against advanced oral squamous cell carcinoma. "
12/01/2010 - "Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma."
11/01/2010 - "Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction."
11/01/2010 - "Temsirolimus inhibited the proliferation and migration of HSC-2 oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. "
08/01/2013 - "This 2-stage phase II study assessed the activity of the mTOR inhibitor, temsirolimus, in patients with measurable metastatic and/or locally advanced, recurrent carcinoma of the cervix. "
08/01/2013 - "Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. "
08/01/2013 - "Single agent temsirolimus has modest activity in cervical carcinoma with about two-thirds of patients exhibiting stable disease. "
10/01/2011 - "Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases."
03/01/2014 - "The mTOR inhibitor temsirolimus has antitumor and antiangiogenic activity against several carcinomas, yet few reports document the efficacy of temsirolimus against malignant pleural mesothelioma (MPM). "
|4.||sorafenib (BAY 43-9006)
|6.||Interferon-alpha (Interferon Alfa)
|10.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)